Light the Way Forward Grant

Light the Way Forward Grant

Funder: The Sumaira Foundation Inc (Brookline, MA) in partnership with Viela Bio

Focus Area: Research to improve understanding of Neuromyelitis Optica Spectrum Disorder (NMOSD) and positively impact those living with NMOSD

Geographic Scope: United States

Eligibility:

Clinical, translational, and basic researchers with experience in NMOSD and related conditions

Must be affiliated with academic institutions in the United States

Award Details:

Up to $25,000 per grant

Award granted to researcher's institution

First-ever medical grant from Viela Bio (established 2021)

Special Characteristics:

Made possible by research grant from Viela Bio

Continuation of partnership between TSF and Viela Bio

Partnership between industry and rare disease advocacy community

Research Focus:
Research aimed at improving understanding of NMOSD pathogenesis, diagnosis, and treatment outcomes

Post-Award Requirements:

Mid-term project report required

Final completion report required

Contact:

Address: The Sumaira Foundation, PO Box 161, Brookline, MA 02446

Website: sumairafoundation.org

Background:

Viela Bio received FDA approval for Uplizna® (inebilizumab-cdon) for NMOSD treatment in June 2020

The Sumaira Foundation is a 501(c)(3) organization founded by an NMO patient dedicated to generating global awareness of NMOSD, fundraising to find a cure, and creating community support for patients and caregivers